Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Monthly Archives: February 2013

Peregrine Pharmaceuticals, Inc. (PPHM) Reveals Results from Phase II Clinical Trial of Bavituximab

Posted on February 13, 2013 by MissionIR

Peregrine Pharmaceuticals is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials focused on the diagnosis and treatment of cancer. The company is pursuing a number of clinical programs in cancer with its lead product candidate, … Continue reading →

Posted in Small Cap News | Leave a comment

Northwest Biotherapeutics, Inc. (NWBO) Video Chart for Wednesday, February 13, 2013

Posted on February 13, 2013 by MissionIR

NWBO had a mild increase in volume on Tuesday as the stock price tried to push through the topside of a channel and the 50-day moving average. This has been a multi-month source of resistance, but if the price breaks … Continue reading →

Posted in Technical Analysis | Leave a comment

Gilat Satellite Networks Ltd. (GILT) Subsidiary Wins Multi-Year, Multi-Site Service Contract from One of the World’s Leading Delivery Service Organizations

Posted on February 13, 2013 by MissionIR

Gilat Satellite Networks, a global leader in satellite networking technology, solutions, and services, announced that its wholly owned subsidiary Spacenet, a prominent supplier of managed network and data security services, recently won a 5-year base contract to upgrade and provide … Continue reading →

Posted in Small Cap News | Leave a comment

Astrotech Corp. (ASTC) Space Operations-California Awarded Task Order Contract by NASA for OCO-2 Spacecraft Processing

Posted on February 13, 2013 by MissionIR

Astrotech, a leading provider of commercial space services, announced that Astrotech Space Operations (ASO), a subsidiary of Astrotech Corporation, has been awarded a NASA task order contract to provide payload processing services for the Orbiting Carbon Observatory – 2 (OCO-2) … Continue reading →

Posted in Small Cap News | Leave a comment

Palatin Technologies, Inc. (PTN) on Cutting-Edge of Receptor-Specific Peptide Therapeutics

Posted on February 12, 2013 by MissionIR

Palatin has put together an exceptionally intricate understanding of the factors which drive agonism via a rational drug design model used to get at key, proprietary small molecule agonist, peptide, and peptide mimetic compounds with tremendous therapeutic upside. The company … Continue reading →

Posted in Small Cap News | Leave a comment

POZEN, Inc. (POZN) Starts Presentation at 15th Annual BIO CEO & Investor Conference

Posted on February 12, 2013 by Mission IR

POZEN is a progressive pharmaceutical company focused on transforming the way unmet medical needs are addressed by the healthcare industry. POZEN has successfully developed two self-invented products in two years, receiving FDA approval for both. Utilizing the funding from these … Continue reading →

Posted in BIO Conference | Leave a comment

OXiGENE, Inc. (OXGN) Starts Presentation at 15th Annual BIO CEO & Investor Conference

Posted on February 12, 2013 by Mission IR

OXiGENE is a clinical-stage biopharmaceutical company engaged in the development of novel therapeutics for treating cancer, with its primary focus on developing vascular disrupting agents that selectively disrupt abnormal blood vessels that are associated with solid tumor progression. The company … Continue reading →

Posted in BIO Conference | Leave a comment

Idenix Pharmaceuticals, Inc. (IDIX) Starts Presentation at 15th Annual BIO CEO & Investor Conference

Posted on February 12, 2013 by Mission IR

Idenix Pharmaceuticals is a biopharmaceutical company dedicated to the discovery and development of drugs for the treatment of human viral diseases. The company’s focus is currently on treating patients with hepatitis C infection. Building on its expertise in nucleoside chemistry … Continue reading →

Posted in BIO Conference | Leave a comment

OncoSec Medical, Inc. (ONCS) Starts Presentation at 15th Annual BIO CEO & Investor Conference

Posted on February 12, 2013 by Mission IR

OncoSec Medical is a biopharmaceutical company focused on developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy for treating solid tumor cancers. The company has based its core technology on its proprietary use of an electroporation platform that dramatically enhances … Continue reading →

Posted in BIO Conference | Leave a comment

Soligenix, Inc. (SNGX) Starts Presentation at 15th Annual BIO CEO & Investor Conference

Posted on February 12, 2013 by Mission IR

Soligenix is a development-stage biopharmaceutical company engaged in developing products for the treatment of serious inflammatory diseases with unmet medical need. The company is developing several biodefense vaccines and therapeutics as well as proprietary formulations of oral BDP for the … Continue reading →

Posted in BIO Conference | Leave a comment